NM
Nir Messafi Portfolio
Invests via Deep Track Capita LLP | Managed by David Kroin
Invests via Deep Track Capita LLP
Managed by David Kroin
Automatically Tracked
Nir Messafi Profile
Nir Messafi is a dynamic entrepreneurial founder with deep expertise in technology-driven startups. With a background in engineering and extensive experience in software development, he has successfully launched several innovative ventures that have redefined industry standards. His commitment to fostering disruptive technologies places him at the forefront of the digital landscape. By bridging the gap between technical innovation and market needs, he plays a crucial role in shaping emerging business models across various sectors. Messafi's ability to identify growth opportunities enables him to navigate complex market challenges, making significant contributions to entrepreneurship and investment landscapes.
Nir Messafi is a dynamic entrepreneurial founder with deep expertise in technology-driven startups. With a background in engineering and extensive experience in software development, he has successfully launched several innovative ventures that have redefined industry standards. His commitment to fostering disruptive technologies places him at the forefront of the digital landscape. By bridging the gap between technical innovation and market needs, he plays a crucial role in shaping emerging business models across various sectors. Messafi's ability to identify growth opportunities enables him to navigate complex market challenges, making significant contributions to entrepreneurship and investment landscapes.
Investment Philosophy & Strategy
With a strong focus on innovation, Nir Messafi seeks transformative opportunities within the technology sector. His entrepreneurial spirit drives him to explore nascent markets where emerging technologies can create significant impact. Capitalizing on his engineering background and software development expertise, he targets investments that promise substantial scalability and differentiation. By understanding customer demands and aligning them with groundbreaking solutions, he positions himself strategically in competitive landscapes. This approach not only fuels growth for his ventures but also contributes to redefining industry standards through operational excellence.
With a strong focus on innovation, Nir Messafi seeks transformative opportunities within the technology sector. His entrepreneurial spirit drives him to explore nascent markets where emerging technologies can create significant impact. Capitalizing on his engineering background and software development expertise, he targets investments that promise substantial scalability and differentiation. By understanding customer demands and aligning them with groundbreaking solutions, he positions himself strategically in competitive landscapes. This approach not only fuels growth for his ventures but also contributes to redefining industry standards through operational excellence.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
198.45%
Gain +2.67%
Monthly
1.65%
Yearly
21.75%
Drawdown
46.78%
$6.54B
Equity
Holdings
$6.54B
Investment
$4.81B
$2.47B
Profit +$91.52M
Realized
$741.78M
Unrealized
$1.73B
Dividends
$2.8M
Goals
Avg. 47.5% completed goals
Yearly
Gain > 5% 2026
Yearly
Gain < 20% 2026
Today
Compared To Yesterday
Gain
2.67%
Profit
$91.52M
Win %
67%
This Week
Compared To Last Week
Gain
1.42%
Profit
$91.52M
Win %
67%
This Month
Compared to last month
Gain
-5.77%
Profit
-$400.78M
Win %
67%
This Year
Compared to last year
Gain
-1.02%
Profit
-$67.17M
Win %
71%
GH Guardant Health Inc.
+6.65%
+$35.49M 
CLDX Celldex Therapeutics Inc.
+6.18%
+$6.7M 
ACRS Aclaris Therapeutics, Inc.
+6.01%
+$2.99M 
WGS GeneDx Holdings Corp.
+5.25%
+$3.13M 
VRDN Viridian Therapeutics Inc.
+4.52%
+$3.45M 
ORKA Oruka Therapeutics, Inc.
+3.92%
+$6.97M 
DFTX Definium Therapeutics, Inc.
+3.5%
+$3.74M 
XFOR X4 Pharmaceuticals Inc.
+3.43%
+$705,450.84 
TNGX Tango Therapeutics Inc.
+3.2%
+$3.19M 
IPSC Century Therapeutics, Inc.
+3.09%
+$567,758.7 
KARD Kardigan, Inc.
+2.86%
+$318,000 
COAG Hemab Therapeutics Holdings, Inc.
+2.72%
+$3.85M 
MANE Veradermics Inc.
+2.7%
+$5.34M 
CNTX Context Therapeutics Inc.
+2.63%
+$68,258.07 
VSTM Verastem Inc.
+2.6%
+$1.09M 
GHRS GH Research plc
+2.54%
+$2.3M 
OCUL Ocular Therapeutix Inc.
+2.19%
+$4.53M 
GENB Generate Biomedicines, Inc.
+1.78%
+$373,468.2 
BCAX Bicara Therapeutics Inc.
+1.71%
+$1.6M 
DYN Dyne Therapeutics Inc.
+1.7%
+$465,000 
NRIX Nurix Therapeutics Inc.
+1.67%
+$3.25M 
CRVS Corvus Pharmaceuticals Inc.
+1.55%
+$498,387.8 
KURA Kura Oncology Inc.
+1.49%
+$336,356.05 
MLTX MoonLake Immunotherapeutics
+1.36%
+$1.19M 
CMPS Compass Pathways plc Depositary Receipt
+1.32%
+$2.31M 
ENTA Enanta Pharmaceuticals Inc.
+1.24%
+$231,066.72 
UTHR United Therapeutics Corporation
+1.12%
+$691,013.44 
BMRN Biomarin Pharmaceutical Inc.
+1.11%
+$2.41M 
ALT Altimmune, Inc.
+0.92%
+$577,500 
CRMD CorMedix Inc.
+0.83%
+$407,814.94 
TARS Tarsus Pharmaceuticals Inc.
+0.81%
+$2.35M 
IMVT Immunovant Inc.
+0.8%
+$2.8M 
MBX MBX Biosciences, Inc.
+0.8%
+$814,307.43 
OLMA Olema Pharmaceuticals Inc.
+0.69%
+$105,000 
IMMX Immix Biopharma Inc.
+0.58%
+$194,250 
GMAB Genmab A/S Sponsored ADR
+0.55%
+$1.02M 
BEAM Beam Therapeutics Inc.
+0.54%
+$130,000 
ALNY Alnylam Pharmaceuticals Inc
+0.53%
+$1.08M 
PSNL Personalis Inc.
+0.49%
+$320,000 
XNCR Xencor Inc.
+0.49%
+$71,226.12 
LBRX LB Pharmaceuticals Inc.
+0.47%
+$704,088.84 
SLDB Solid Biosciences Inc.
+0.46%
+$142,602.48 
ALMS Alumis Inc.
+0.44%
+$253,942.32 
AVTX Avalo Therapeutics Inc.
+0.37%
+$216,600 
MAZE Maze Therapeutics Inc.
+0.28%
+$261,279.83 
ELVN Enliven Therapeutics, Inc.
+0.2%
+$24,750 
PCVX Vaxcyte, Inc.
+0.12%
+$301,000 
ATAI AtaiBeckley Inc.
0%
$0 
COGT Cogent Biosciences, Inc.
0%
$0 
MNKD MannKind Corporation
0%
$0 
NUVL Nuvalent, Inc.
0%
$0 
STTK Shattuck Labs Inc.
0%
$0 
IONS Ionis Pharmaceuticals, Inc.
-5.11%
-$6.09M 
IVA Inventiva S.A.
-3.48%
-$112,000 
ALGS Aligos Therapeutics Inc.
-3.45%
-$79,939.8 
VERA Vera Therapeutics Inc.
-2.85%
-$4M 
PMN ProMIS Neurosciences, Inc.
-2.21%
-$250,696.5 
AXSM Axsome Therapeutics, Inc.
-1.89%
-$2.92M 
NKTR Nektar Therapeutics Inc.
-1.81%
-$378,000 
CYTK Cytokinetics, Incorporated
-1.79%
-$924,000 
KLRA Kailera Therapeutics, Inc.
-1.36%
-$133,000 
HROW Harrow Inc.
-1.19%
-$397,290 
GRAL Grail, Inc.
-0.92%
-$1.28M 
GPCR Structure Therapeutics Inc.
-0.57%
-$1.04M 
IMCR Immunocore Holdings plc American Depositary Receipt
-0.43%
-$43,570.52 
ALKS Alkermes plc
-0.3%
-$560,000 Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 904 | Longs Won 454/904 50% | Profit Factor 2.44 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $16.09M |
| Average Win $9.24M | Best Trade (Sep 14) $217.43M | Sharpe Ratio -33.55 |
| Average Loss -$3.83M | Worst Trade (Sep 14) -$82.53M | Z-Score -0.17 (13.17%) |
| Commissions $0 | Avg. Trade Length 11m 4w 1d | Expectancy $2.74M |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 1,709 | 1,538 | 1,368 | 1,197 | 1,026 | 855 | 684 | 513 | 342 | 171 |
Hover over the desired column for a detailed explanation.
Returns
Overall, Monthly| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
| ACRS Aclaris Therapeutics, Inc. | 9.35M | $35.04M | $52.71M | - | $17.66M | 50.4% | +6.015% |
| ALGS Aligos Therapeutics Inc. | 444,110 | $3.76M | $2.24M | - | -$1.53M | -40.53% | -3.448% |
| ALKS Alkermes plc | 4M | $131.89M | $183.32M | - | $51.43M | 39% | -0.305% |
| ALMS Alumis Inc. | 6.35M | $139.86M | $58.53M | - | -$81.33M | -58.15% | +0.436% |
| ALNY Alnylam Pharmaceuticals Inc | 825,000 | $248.35M | $206.24M | - | -$42.11M | -16.96% | +0.527% |
| ALT Altimmune, Inc. | 19.25M | $58.52M | $63.52M | - | $5M | 8.55% | +0.917% |
| ATAI AtaiBeckley Inc. | 14.42M | $52.39M | $105.97M | - | $53.58M | 102.26% | 0.0 |
| AVTX Avalo Therapeutics Inc. | 3.61M | $69.64M | $58.41M | - | -$11.23M | -16.12% | +0.372% |
| AXSM Axsome Therapeutics, Inc. | 700,000 | $94.32M | $151.61M | - | $57.29M | 60.74% | -1.889% |
| BCAX Bicara Therapeutics Inc. | 4.1M | $78.3M | $95.12M | - | $16.82M | 21.49% | +1.71% |
| BEAM Beam Therapeutics Inc. | 1M | $25.63M | $24.12M | - | -$1.51M | -5.91% | +0.542% |
| BMRN Biomarin Pharmaceutical Inc. | 3.31M | $192.77M | $219.65M | - | $26.88M | 13.95% | +1.111% |
| CLDX Celldex Therapeutics Inc. | 2.94M | $90.76M | $115.16M | - | $24.4M | 26.88% | +6.179% |
| CMPS Compass Pathways plc Depositary Receipt | 12.16M | $47.67M | $176.83M | - | $129.16M | 270.94% | +1.324% |
| CNTX Context Therapeutics Inc. | 7.42M | $14.88M | $2.67M | - | -$12.21M | -82.06% | +2.626% |
| COAG Hemab Therapeutics Holdings, Inc. | 3.6M | $99.85M | $145.78M | - | $45.93M | 46% | +2.716% |
| COGT Cogent Biosciences, Inc. | 2M | $75.15M | $66.82M | - | -$8.33M | -11.09% | 0.0 |
| CRMD CorMedix Inc. | 6.27M | $68.13M | $49.5M | - | -$18.63M | -27.34% | +0.831% |
| CRVS Corvus Pharmaceuticals Inc. | 2.49M | $36.46M | $32.67M | - | -$3.79M | -10.39% | +1.549% |
| CYTK Cytokinetics, Incorporated | 700,000 | $37.38M | $50.72M | - | $13.34M | 35.69% | -1.789% |
No Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
FAQ
Which stocks have generated the highest profits for Nir Messafi?
The largest contributions to the portfolio's profits come from the following stocks: Insmed Inc - $251.52M, Immunovant Inc - $243.37M, Ionis Pharmaceuticals, Inc - $142.19M, Guardant Health Inc - $133.87M, and Axsome Therapeutics, Inc - $88.18M. These positions have been the main drivers of growth and have significantly impacted the investor's overall performance.
Which stocks have generated the largest losses for this investor?
The largest losses in the portfolio are associated with the following stocks: Pliant Therapeutics Inc - $117.01M, Bicycle Therapeutics plc American Depositary Receipt - $88.58M, Travere Therapeutics Inc - $77.95M, Fate Therapeutics Inc - $62.41M, and 4D Molecular Therapeutics, Inc - $58.81M. These positions have had the most negative impact on overall performance and highlight the weaker areas of the portfolio.
What dividends does Nir Messafi's portfolio generate?
The portfolio generates substantial dividend income, with a total of $2.8M earned over time. The largest contributors to dividend income include Amgen Inc - $2.8M. This indicates that dividends play a meaningful role in the investor's overall strategy.
How stable are Nir Messafi's monthly returns?
Nir Messafi's monthly returns look highly volatile. The portfolio shows large month-to-month swings, and the broader risk profile suggests that performance can change sharply over short periods. This kind of pattern may suit users who are comfortable with significant fluctuations, but it is less likely to appeal to those who prefer steadier and more predictable results.
Can Nir Messafi's strategy be considered aggressive or moderate?
Nir Messafi's strategy can be considered aggressive. The combination of high drawdowns, elevated volatility, and/or concentrated positions suggests a willingness to accept significant risk in pursuit of higher long-term returns. This approach is generally more suitable for users who are comfortable with large fluctuations in portfolio value.
Should beginners follow Nir Messafi's strategy?
Nir Messafi's strategy is unlikely to be suitable for beginners. The portfolio shows signs of high risk, significant volatility, or structural complexity, which can make it difficult to follow and potentially stressful for less experienced users. This type of approach is generally better suited to more advanced investors.
